

# Jonathan Loree

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1527814/publications.pdf>

Version: 2024-02-01

76  
papers

3,024  
citations

257450

24  
h-index

182427

51  
g-index

79  
all docs

79  
docs citations

79  
times ranked

5051  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. <i>JAMA Oncology</i> , 2019, 5, e191870.	7.1	348
2	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 164-173.	9.4	243
3	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	7.0	225
4	Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 831.	7.1	221
5	Clinical and molecular characterization of early-onset colorectal cancer. <i>Cancer</i> , 2019, 125, 2002-2010.	4.1	212
6	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. <i>Annals of Oncology</i> , 2019, 30, 243-249.	1.2	170
7	Platelet "first responders" in wound response, cancer, and metastasis. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 199-213.	5.9	127
8	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2019, 269, 917-923.	4.2	121
9	Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. <i>BMC Cancer</i> , 2020, 20, 288.	2.6	86
10	Recent developments in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 551-564.	3.2	82
11	Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. <i>Journal of Clinical Oncology</i> , 2022, 40, 2846-2857.	1.6	77
12	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 6899-6908.	7.0	76
13	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4578-4591.	7.0	70
14	Radiation-induced molecular changes in rat mammary tissue: Possible implications for radiation-induced carcinogenesis. <i>International Journal of Radiation Biology</i> , 2006, 82, 805-815.	1.8	66
15	Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Translational Oncology</i> , 2018, 11, 1188-1201.	3.7	57
16	Molecular Landscape of <i>ERBB2/ERBB3</i> Mutated Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1409-1417.	6.3	53
17	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-"Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	46
18	Patient and family financial burden associated with cancer treatment in Canada: a national study. <i>Supportive Care in Cancer</i> , 2021, 29, 3377-3386.	2.2	43

#	ARTICLE	IF	CITATIONS
19	Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. <i>Clinical Colorectal Cancer</i> , 2018, 17, e699-e709.	2.3	34
20	Impact of Travel Distance and Urbanâ€Rural Status on the Multidisciplinary Management of Rectal Cancer. <i>Journal of Rural Health</i> , 2017, 33, 393-401.	2.9	33
21	Current and Emerging Biomarkers in Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2019, 26, 7-15.	2.2	31
22	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002329.	1.2	30
23	Predictors of Local Control of Brain Metastasis Treated With Laser Interstitial Thermal Therapy. <i>Neurosurgery</i> , 2020, 87, 112-122.	1.1	30
24	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1663-1670.	7.0	30
25	Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives. <i>Current Oncology</i> , 2021, 28, 671-677.	2.2	27
26	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 199-212.	1.4	26
27	Population-based Screening for <i>BRAF</i> V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. <i>Clinical Cancer Research</i> , 2020, 26, 4599-4605.	7.0	26
28	Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. <i>Clinical Cancer Research</i> , 2021, 27, 3414-3421.	7.0	25
29	Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 156-163.	2.3	24
30	Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. <i>Clinical Cancer Research</i> , 2021, 27, 150-157.	7.0	24
31	Untying the gordian knot of targeting MET in cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 95-103.	7.7	18
32	Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003814.	1.2	17
33	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 137-147.e1.	2.3	17
34	Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?. <i>Clinical Cancer Research</i> , 2021, 27, 246-254.	7.0	16
35	Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. <i>Oncologist</i> , 2021, 26, 107-114.	3.7	16
36	Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	14

#	ARTICLE	IF	CITATIONS
37	Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 522-531.	7.0	14
38	Trends in the incidence of young-onset colorectal cancer with a focus on years approaching screening age: A population-based longitudinal study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 863-868.	6.3	14
39	Clinical and Functional Characterization of Atypical <i>KRAS</i> / <i>NRAS</i> Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4587-4598.	7.0	14
40	Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 65-72.	2.3	14
41	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. <i>Cell Reports</i> , 2021, 37, 109817.	6.4	14
42	Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy. <i>Clinical Colorectal Cancer</i> , 2016, 15, 352-359.e1.	2.3	12
43	Optimizing adjuvant therapy and survivorship care of stage III colon cancer. <i>Future Oncology</i> , 2016, 12, 2021-2035.	2.4	12
44	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	3.0	12
45	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 196-201.	1.3	12
46	Expanded Low Allele Frequency <i>RAS</i> and <i>BRAF</i> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 52-59.	7.0	12
47	Health information seeking behaviors among individuals with young-onset and average-onset colorectal cancer: an international cross-sectional survey. <i>Supportive Care in Cancer</i> , 2020, 28, 6011-6021.	2.2	11
48	Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?. <i>Current Oncology</i> , 2021, 28, 1558-1570.	2.2	11
49	Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1889-1897.	4.1	10
50	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. <i>Oncotarget</i> , 2017, 8, 57882-57888.	1.8	10
51	Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. <i>Oncologist</i> , 2020, 25, 229-234.	3.7	9
52	Hereditary and Inflammatory Bowel Disease-Related Early Onset Colorectal Cancer Have Unique Characteristics and Clinical Course Compared with Sporadic Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1785-1791.	2.5	9
53	Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 711-714.	1.3	7
54	Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 643-648.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases. <i>Case Reports in Oncology</i> , 2016, 9, 76-82.	0.7	7
56	Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 596-596.	1.6	7
57	Why a One Size Fits All Approach to <i>RAS</i> Might Not Fit Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 545-547.	4.9	6
58	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. <i>JCO Precision Oncology</i> , 2020, 4, 1152-1162.	3.0	6
59	Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-5.	1.9	6
60	Cranial magnetic resonance imaging findings of leptomeningeal contrast enhancement after pediatric posterior fossa tumor resection and its significance. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 6, 87-91.	1.3	5
61	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 11.	3.0	3
62	Report from the 19th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29â€“30 September 2017. <i>Current Oncology</i> , 2018, 25, 275-284.	2.2	3
63	Underreporting of race/ethnicity in COVID-19 research. <i>International Journal of Infectious Diseases</i> , 2021, 108, 419-421.	3.3	3
64	Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 48-56.e2.	2.3	2
65	Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers. <i>Clinical Colorectal Cancer</i> , 2022, 21, 107-113.	2.3	2
66	A case of pediatric anaplastic large cell lymphoma with hemophagocytic lymphohistiocytosis mimicking juvenile myelomonocytic leukemia. <i>Journal of Hematopathology</i> , 2011, 4, 21-29.	0.4	1
67	Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28â€“29 September 2018. <i>Current Oncology</i> , 2019, 26, 773-784.	2.2	1
68	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 132-136.e3.	2.3	1
69	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. <i>Journal of Surgical Oncology</i> , 2020, 121, 984-989.	1.7	1
70	FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS / BRAF Wild-Type Colorectal Cancer: Which Side Are You On?. <i>Oncologist</i> , 2021, 26, 277-280.	3.7	1
71	Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors. <i>American Journal of Surgery</i> , 2021, 221, 1141-1149.	1.8	1
72	Sequence of Therapy and Survival in Patients with Advanced Pancreatic Neuroendocrine Tumours. <i>Current Oncology</i> , 2020, 27, 215-219.	2.2	0

#	ARTICLE	IF	CITATIONS
73	Clinical application of cfDNA: moving in the right direction, but still a long way to go. <i>Oncotarget</i> , 2018, 9, 35199-35200.	1.8	0
74	Real-world treatment attrition rates in advanced esophagogastric cancer. <i>World Journal of Gastroenterology</i> , 2020, 26, 6027-6036.	3.3	0
75	Immunosuppression and COVID-19 infection in British Columbia: Protocol for a linkage study of population-based administrative and self-reported survey data. <i>PLoS ONE</i> , 2021, 16, e0259601.	2.5	0
76	The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. <i>Journal of Molecular Diagnostics</i> , 2022, , .	2.8	0